JP2003513039A5 - - Google Patents

Download PDF

Info

Publication number
JP2003513039A5
JP2003513039A5 JP2001534373A JP2001534373A JP2003513039A5 JP 2003513039 A5 JP2003513039 A5 JP 2003513039A5 JP 2001534373 A JP2001534373 A JP 2001534373A JP 2001534373 A JP2001534373 A JP 2001534373A JP 2003513039 A5 JP2003513039 A5 JP 2003513039A5
Authority
JP
Japan
Prior art keywords
antioxidant
composition
carnitine
administered
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001534373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003513039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/030571 external-priority patent/WO2001032168A1/en
Publication of JP2003513039A publication Critical patent/JP2003513039A/ja
Publication of JP2003513039A5 publication Critical patent/JP2003513039A5/ja
Pending legal-status Critical Current

Links

JP2001534373A 1999-11-03 2000-11-02 良性の健忘症を治療する方法 Pending JP2003513039A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16335299P 1999-11-03 1999-11-03
US22316700P 2000-08-07 2000-08-07
US60/163,352 2000-08-07
US60/223,167 2000-08-07
PCT/US2000/030571 WO2001032168A1 (en) 1999-11-03 2000-11-02 Method of treating benign forgetfulness

Publications (2)

Publication Number Publication Date
JP2003513039A JP2003513039A (ja) 2003-04-08
JP2003513039A5 true JP2003513039A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=26859574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534373A Pending JP2003513039A (ja) 1999-11-03 2000-11-02 良性の健忘症を治療する方法

Country Status (5)

Country Link
US (1) US6335361B1 (cg-RX-API-DMAC10.html)
EP (1) EP1248609A4 (cg-RX-API-DMAC10.html)
JP (1) JP2003513039A (cg-RX-API-DMAC10.html)
CA (1) CA2389623A1 (cg-RX-API-DMAC10.html)
WO (1) WO2001032168A1 (cg-RX-API-DMAC10.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US8592479B2 (en) * 2000-10-31 2013-11-26 Hill's Pet Nutrition, Inc. Antioxidant-containing food composition for use in enhancing antiviral immunity in companion animals
CN1477958A (zh) * 2000-10-31 2004-02-25 高露洁-棕榄公司 组合物及方法
US20090156658A1 (en) * 2000-10-31 2009-06-18 Hill's Pet Nutrition, Inc. Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
WO2002038142A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
BR0207948A (pt) * 2001-03-09 2004-07-27 Produits Nestel S A Soc D Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade
DE10125901A1 (de) * 2001-05-28 2002-12-05 Basf Ag Kombination von Liponsäuren, Carnitinen und Kreatinen in Lebens- und Arzneimitteln
US6923960B2 (en) 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
JP4602075B2 (ja) 2002-05-06 2010-12-22 トーマス・ジェファーソン・ユニバーシティ 脳の健康に効果のあるインスリン関連ペプチド
WO2003101402A2 (en) * 2002-06-04 2003-12-11 Avicena Group, Inc. Methods of treating cognitive dysfunction by modulating brain energy metabolism
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US7326690B2 (en) * 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US20060165671A1 (en) * 2002-11-07 2006-07-27 Daniel Raederstorff Novel nutraceutical compositions comprising epigallocatechin gallate
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
WO2005032278A1 (en) 2003-09-29 2005-04-14 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US20050102171A1 (en) * 2003-10-29 2005-05-12 Ashley Thomas R. Elderly assessment protocol
ES2550952T3 (es) * 2004-11-24 2015-11-13 Hill's Pet Nutrition, Inc. Composición para su uso en la mejora del aclaramiento hepático de sustancias xenobióticas en un animal
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
BRPI0519642A8 (pt) * 2004-12-29 2017-10-03 Hill´S Pet Nutrition Inc Método para inibir um declínio em aprendizagem e/ou memória, kit apropriado para administrar um ou mais antioxidantes a um animal, meio para transmitir informação, e, uso de uma composição
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
WO2006092449A2 (en) * 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
BRPI0613000A2 (pt) 2005-07-14 2012-12-04 Hills Pet Nutrition Inc método para aumentar a longevidade de um animal, artigo de fabricação, kit, e, meio de comunicação de informação acerca de ou instruções para a administração a um animal velho de uma composição
US20090246186A1 (en) 2006-03-29 2009-10-01 Kaneka Corporation Agent for improving nervous system cell functions
US20070292403A1 (en) * 2006-05-11 2007-12-20 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
JP5119509B2 (ja) * 2006-05-18 2013-01-16 ビーエイチエヌ株式会社 活動意欲向上剤
US8883814B2 (en) 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
US10105406B2 (en) 2006-06-05 2018-10-23 Keyview Labs, Inc. Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A, Ginkgo biloba, and vitamin B complex
US8071610B2 (en) * 2006-06-05 2011-12-06 Josh Reynolds Compositions and methods for enhancing brain function
US9308232B2 (en) 2006-06-05 2016-04-12 Keyview Labs, Inc. Compositions and methods for enhancing brain function
WO2007145993A2 (en) * 2006-06-05 2007-12-21 Brite Age Modified compositions and methods for enhancing brain function
US20070281961A1 (en) * 2006-06-05 2007-12-06 Brite Age Modified Compositions And Methods For Enhancing Brain Function
US10105405B2 (en) 2006-06-05 2018-10-23 Keyview Labs, Inc. Compositions and methods for enhancing brain function using acetyl-L-carnitine, huperzine A and ginkgo biloba
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
JP2008214338A (ja) * 2007-02-08 2008-09-18 Shiseido Co Ltd 高次脳機能低下改善剤および遅延記憶低下改善剤
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
JP5157007B2 (ja) * 2007-05-11 2013-03-06 ビーエイチエヌ株式会社 骨強化剤
DE102007030495A1 (de) 2007-06-30 2009-01-15 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
KR20120129898A (ko) 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
AU2013358951C1 (en) 2012-12-13 2019-06-27 Baylor Research Institute Triheptanoin for the treatment of glucose transporter 1 deficiency
AU2014348457B2 (en) 2013-11-14 2019-04-18 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
JP2015193582A (ja) * 2014-03-28 2015-11-05 国立大学法人 東京大学 イミダゾールジペプチドを含む剤
CN112190688A (zh) * 2020-09-09 2021-01-08 广州医科大学附属第一医院(广州呼吸中心) 粘蛋白muc1在制备具有延缓肺衰老功效的药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
IT1156840B (it) 1978-06-27 1987-02-04 Sigma Tau Ind Farmaceuti Acil derivati della carnitina
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1145362B (it) 1980-03-06 1986-11-05 Sigma Tau Ind Farmaceuti Classe di acil-derivati della carnitina procedimento per la loro preparazione e loro uso terapeutico
CH655005A5 (it) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US4871718A (en) 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair
IT1230142B (it) 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
US5240961A (en) 1992-07-02 1993-08-31 Shug Austin L Method of treating reduced insulin-like growth factor and bone loss associated with aging
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil

Similar Documents

Publication Publication Date Title
DE69927125D1 (de) Zusammensetzung gegen Erhöhung oder zur Herabsetzung des Blutzuckerspiegels
FR2807322B1 (fr) Composition, notamment cosmetique, comprenant de l'acide ascorbique en association avec un derive d'acide ascorbique
WO2004083369A3 (fr) Composition de fixation tissulaire
WO2001062290A3 (en) Methods and compositions for improving sleep
MXPA03005155A (es) 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos.
IL145344A0 (en) Food complement and method for cosmetic treatment based on a grape extract rich in polyphenols
DE60124047D1 (de) Ferulasäure und Coffeinsäure oder Chlorogensäure enthaltende Zusammensetzungen zur Linderung von Bluthochdruck oder zur Verhinderung der Erhöhung des Blutdrucks
FR2840903B1 (fr) Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
DK0760238T3 (da) Præparat, der kan indgives perkutant, til behandling af vandladningslidelse
WO2002009679A3 (en) Use of 13-cis retinoic acid for the treatment of emphysema
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
WO2005079396A3 (en) O,o'-amidomalonate and n,o-amidomalonate platinum complexes
AU2001242130A1 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
PL362577A1 (en) Increase in the vitamin e content in organisms due to an increase in the tyrosine aminotransferase activity
CA2417837A1 (en) Compositions for ameliorating attention-deficient/hyperactivity disorder
EP1709960A3 (en) Use of alkanoic acid-containing compositions for straightening hair
EP1806144A3 (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
WO2003094905A8 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
WO2004074216A3 (en) Carnitine salt, preliposome which contains it and dermo-cosmetic formula for topical use based upon said carnitine salt
JP2003501387A5 (cg-RX-API-DMAC10.html)
ITRM20000602A0 (it) Composizione per la prevenzione e/o il trattamento di alterazioni delmetabolismo lipidico, delle forme allergiche e per attivare le difese
WO2000006138A3 (en) Use of moclobemide for treating pain and other diseases
MD916G2 (ro) Unguent pentru tratamentul afecţiunilor dentare
EP1315499A4 (en) COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES
EP1671636A4 (en) IMPROVED FIXED 5-AMINOSALICYLIC ACID PREPARATION AND STORAGE METHOD FOR TREATING THEREOF